August 16th, 2013
Abbott Labs Accused of Racketeering in Depakote Marketing Suit
By Andrew Harris
Abbott Laboratories (ABT:US) allegedly engaged in racketeering when it led an effort to market the epilepsy drug Depakote for unapproved uses, according to a federal court complaint filed in Chicago.
The pharmaceutical company last year agreed to pay $1.6 billion to settle state and federal claims it promoted the drug’s use to treat bi-polar mania and to prevent migraine headaches.